Literature DB >> 22358376

[Resection of metastases from prostate cancer].

C-H Ohlmann1, S Siemer, M Stöckle.   

Abstract

Surgical resection of a solitary or a limited number of metastases is a controversy in patients with prostate cancer that is increasingly being discussed. The improved accuracy of the detection of local or distant recurrences after primary treatment using modern imaging techniques including choline PET/CT led to an increased demand for salvage surgical procedures. Apart from the resection of synchronous metastases at the time of radical prostatectomy the oncological efficacy of a salvage lymphadenectomy or a salvage resection of visceral or osseous metastases remains to be proven. Here, the available data covering the different clinical scenarios for the resection of metastases in prostate cancer and recommendations of recently published guidelines are reviewed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22358376     DOI: 10.1007/s00120-012-2827-4

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  32 in total

1.  Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?

Authors:  Pia Bader; Fiona C Burkhard; Regula Markwalder; Urs E Studer
Journal:  J Urol       Date:  2003-03       Impact factor: 7.450

2.  Simultaneous FDG PET+/Glut1+ lung and FDG PET-/Glut1- subcarinal lymph node metastases from prostate cancer.

Authors:  Amir H Khandani; William K Funkhouser; Richard Feins; Mark A Socinski
Journal:  Ann Nucl Med       Date:  2009-05-13       Impact factor: 2.668

3.  [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy.

Authors:  Ludwig Rinnab; Joerg Simon; Richard E Hautmann; M V Cronauer; Kathrin Hohl; Andreas K Buck; Sven N Reske; Felix M Mottaghy
Journal:  World J Urol       Date:  2009-02-21       Impact factor: 4.226

4.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Authors:  Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni
Journal:  Eur Urol       Date:  2010-10-28       Impact factor: 20.096

5.  [Surgical treated pulmonary metastasis from prostatic cancer; report of a case].

Authors:  Takehiro Sakai; Daisuke Kimura; Ryo Hatanaka; Yoshitsugu Yamada; Takao Tsushima; Ikuo Fukuda; Yoshimasa Kamata
Journal:  Kyobu Geka       Date:  2010-04

6.  [A case of solitary endobronchial metastasis of prostatic cancer].

Authors:  Tadaaki Yamada; Taichiro Arimoto; Nobuyo Komatani; Hiroshi Hara
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2004-11

7.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Authors:  Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Hans-Peter Schmid; Theo Van der Kwast; Thomas Wiegel; Filiberto Zattoni; Axel Heidenreich
Journal:  Eur Urol       Date:  2011-01-25       Impact factor: 20.096

Review 8.  Lymph node positive prostate cancer: long-term survival data after radical prostatectomy.

Authors:  Ulrike Zwergel; Jan Lehmann; Bernd Wullich; Ulrich Schreier; Klaus Remberger; Thomas Zwergel; Michael Stoeckle
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

9.  Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.

Authors:  David Schilling; Heinz P Schlemmer; Philipp H Wagner; Patrick Böttcher; Axel S Merseburger; Philip Aschoff; Roland Bares; Christa Pfannenberg; Ute Ganswindt; Stefan Corvin; Arnulf Stenzl
Journal:  BJU Int       Date:  2008-04-11       Impact factor: 5.588

10.  The Role of C-Choline-PET/CT-Guided Secondary Lymphadenectomy in Patients with PSA Failure after Radical Prostatectomy: Lessons Learned from Eight Cases.

Authors:  Thomas Martini; Roman Mayr; Emanuela Trenti; Salvatore Palermo; Evi Comploj; Armin Pycha; Maria Zywica; Michele Lodde
Journal:  Adv Urol       Date:  2011-07-31
View more
  2 in total

Review 1.  [Resecting hematogenous metastases: reasons against].

Authors:  F C Roos; J W Thüroff
Journal:  Urologe A       Date:  2014-06       Impact factor: 0.639

2.  Role of RUNX3 in suppressing metastasis and angiogenesis of human prostate cancer.

Authors:  Feifei Chen; Meng Wang; Jin Bai; Qinghua Liu; Yaguang Xi; Wang Li; Junnian Zheng
Journal:  PLoS One       Date:  2014-01-24       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.